Pre-clinical data shows Angiocidin effective against leukemia
Angiocidin, a novel tumor-inhibiting protein, has been shown to reduce acute myeloid leukemia (AML) cells in vivo by almost two-thirds in pre-clinical experiments.
Dec 9, 2012
0
0
Angiocidin, a novel tumor-inhibiting protein, has been shown to reduce acute myeloid leukemia (AML) cells in vivo by almost two-thirds in pre-clinical experiments.
Dec 9, 2012
0
0
A potent chemotherapy agent wrapped within a monoclonal antibody selectively destroys the malignant cells responsible for acute lymphocytic leukemia (ALL) in either weekly or monthly dosing, researchers report at the 54th ...
Dec 11, 2012
0
0
Chemotherapy is one of the primary treatments for cancer. However, one of the most disturbing findings of recent studies of cancer survivors is the apparent prevalence of chemotherapy-associated adverse neurological effects, ...
Jul 15, 2013
0
0
Increasing the dose intensity of chemotherapy by either shortening the intervals between the cycles or by sequential administration instead of concurrent administration of the drugs reduced the risk of early-stage breast ...
Dec 6, 2017
0
1
African-American women who survive breast cancer are more likely to develop heart failure than other women who have beaten the disease, according to research being presented at the American College of Cardiology's 62nd Annual ...
Mar 7, 2013
0
0